We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022



The content on this page is intended for members of the public.


Names and Compounds of our Products 

Lundbeck has a broad range of products within brain diseases. With registered products in more than 100 countries, we leverage our global presence to bring innovative therapies to people living with brain diseases around the world.

Report An Adverse Event:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.


Adverse events should also be reported to Lundbeck Limited, Medical Information on 01908 638972 or at SafetyLuUnitedKingdom@lundbeck.com.

Report an Adverse Drug Reaction

Reporting of potential adverse drug reactions is important in order for us to continuously evaluate the benefits and risks of our products and take proactive action as warranted.

Lundbeck Ltd UK Distributed or Promoted Products  


All our products are prescription-only medicines (POM). If more information is required, please refer to the local Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) using the links below.

For Abilify® (aripiprazole) and Abilify Maintena® (aripiprazole), medicines which are marketed jointly with Otsuka who are the Marketing Authorisation (MA) holder, please use the links below. All other medicines can be found at the links above. 

More from lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.


We see patients as people and are committed to support the person behind.


Discover our projects and compounds in development. 

UK-NOTPR-1780 | February 2024